Strasbourg, France, October 22, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will participate in the Jefferies 2019 London Healthcare Conference on November 20 & 21 in London (United Kingdom).
The management will meet with leading European Healthcare investors to present its innovative immunotherapy portfolio and detail the promising clinical results obtained with the combination regimen of TG4001 in HPV-positive cancers.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer